introduct
aetiolog
acut
exacerb
chronic
obstruct
pulmonari
diseas
copd
remain
incomplet
understood
strategi
treatment
prevent
alter
significantli
mani
year
improv
understand
role
respiratori
pathogen
acut
exacerb
copd
aecopd
requir
use
molecular
microbiolog
techniqu
may
lead
insight
hostpathogen
interact
develop
target
therapeut
approach
trial
registr
number
clinicaltrialsgov
bourn
cohet
c
kim
v
et
al
respiratori
infect
copd
aeri
longitudin
epidemiolog
studi
assess
chang
copd
airway
microbiom
contribut
incid
sever
aecopd
patient
copd
age
follow
monthli
year
review
within
h
onset
symptom
aecopd
exacerb
detect
use
daili
electron
diari
card
blood
sputum
nasopharyng
urin
sampl
collect
prespecifi
timepoint
molecular
diagnost
type
techniqu
use
describ
dynam
airway
infect
aecopd
stabl
diseas
associ
clinic
outcom
studi
aim
refin
case
definit
aecopd
reflect
possibl
microbiolog
aetiolog
aeri
assess
impact
aecopd
healthrel
qualiti
life
healthcar
resourc
utilis
possibl
interact
nutrit
statu
infect
immun
respons
ethic
dissemin
aeri
conduct
accord
declar
helsinki
good
clinic
practic
approv
institut
ethic
review
board
particip
must
provid
written
inform
consent
result
obtain
dissemin
intern
medic
confer
peerreview
public
discuss
studi
address
complex
microbiolog
system
compon
copd
employ
realtim
electron
track
symptom
identifi
aecopd
potenti
aetiolog
trigger
result
result
aeri
increas
understand
contribut
pathogen
aecopd
potenti
lead
new
target
therapeut
prevent
intervent
chronic
obstruct
pulmonari
diseas
copd
inflammatori
diseas
lung
characteris
progress
airflow
limit
fulli
revers
copd
common
chronic
respiratori
ill
older
adult
affect
estim
million
peopl
worldwid
condit
substanti
impact
qualiti
life
global
burden
diseas
studi
found
copd
third
lead
caus
death
global
ninth
lead
caus
year
life
lost
due
prematur
mortal
account
year
live
disabl
disabilityadjust
strength
limit
studi
conduct
specialis
hospit
extens
experi
respiratori
research
comprehens
assess
clinic
statu
microbiolog
function
statu
nutrit
statu
healthrel
qualiti
life
healthcar
resourc
utilis
individu
patient
singl
larg
cohort
stabl
chronic
obstruct
pulmonari
diseas
copd
acut
exacerb
copd
aecopd
aecopd
proactiv
identifi
patientcomplet
electron
diari
cohort
retent
key
factor
success
deliveri
studi
indepth
sampl
protocol
particip
engag
comfort
feedback
key
factor
optimis
cohort
retent
comprehens
data
collect
life
year
worldwid
copd
also
impos
substanti
socioeconom
burden
total
cost
copd
europ
report
billion
consider
progress
made
concern
epidemiolog
pathophysiolog
clinic
manag
copd
recent
year
howev
signific
challeng
remain
improv
understand
acut
exacerb
copd
aecopd
key
research
prioriti
aecopd
highli
relev
clinic
major
caus
copdrel
morbid
mortal
well
account
substanti
proport
signific
social
healthcar
econom
burden
copd
estim
aecopd
account
approxim
total
healthcar
cost
associ
copd
patient
global
initi
chronic
obstruct
lung
diseas
gold
stage
ii
diseas
greater
experi
one
two
exacerb
annual
exacerb
vari
patient
patient
sever
diseas
variou
trigger
aecopd
identifi
howev
exacerb
associ
detect
bacteri
andor
viral
respiratori
pathogen
exacerb
associ
detect
respiratori
pathogen
shown
mark
impact
lung
function
longer
durat
hospitalis
exacerb
noninfecti
aetiolog
introduct
new
molecular
sequenc
techniqu
tradit
belief
healthi
lung
steril
refut
increas
evid
lower
respiratori
tract
contain
divers
microbi
flora
differ
health
diseas
presenc
potenti
pathogen
microorgan
inflam
airway
patient
copd
well
document
patient
stabl
copd
show
evid
lower
airway
bacteri
colonis
use
tradit
cultur
techniqu
patient
copd
bacteri
detect
lower
airway
deriv
sampl
associ
increas
airway
inflamm
reduc
lung
function
frequent
exacerb
acquisit
new
pathogen
strain
also
appear
associ
increas
risk
aecopd
estim
rel
contribut
differ
pathogen
aecopd
vari
howev
nontyp
haemophilu
influenza
appear
major
bacteri
pathogen
associ
aecopd
follow
streptococcu
pneumonia
moraxella
catarrhali
pseudomona
aeruginosa
respiratori
virus
commonli
associ
aecopd
divers
includ
human
rhinovirus
influenza
parainfluenza
virus
respiratori
syncyti
viru
coronaviru
adenoviru
improv
understand
role
infecti
pathogen
aecopd
requir
better
understand
pathophysiolog
diseas
may
lead
develop
target
strategi
treatment
prevent
articl
describ
object
design
acut
exacerb
respiratori
infect
copd
aeri
prospect
longitudin
epidemiolog
studi
initi
uk
assess
role
respiratori
infect
aecopd
molecular
diagnost
type
techniqu
use
describ
dynam
airway
infect
potenti
associ
clinic
outcom
studi
also
assess
impact
aecopd
healthrel
qualiti
life
healthcar
resourc
utilis
well
possibl
interact
diseas
endotyp
exacerb
primari
object
aeri
studi
estim
incid
allcaus
aecopd
aecopd
sputum
contain
bacteri
pathogen
overal
speci
secondari
studi
object
summaris
tabl
ongo
singlecentr
prospect
observ
cohort
studi
base
univers
hospit
southampton
uk
tabl
overview
primari
secondari
object
aeri
studi
primari
estim
incid
rate
allcaus
aecopd
estim
incid
rate
aecopd
sputum
contain
bacteri
pathogen
overal
speci
secondari
describ
proport
overal
specif
bacteri
pathogen
detect
sputum
sever
aecopd
describ
proport
overal
specif
bacteri
pathogen
detect
sputum
stabl
copd
estim
incid
rate
aecopd
sputum
contain
viral
pathogen
overal
speci
describ
proport
overal
specif
viral
pathogen
detect
sputum
sever
aecopd
estim
time
elaps
consecut
aecopd
episod
assess
impact
allcaus
aecopd
stabl
copd
healthrel
qualiti
life
assess
impact
healthcar
use
allcaus
aecopd
aecopd
sputum
contain
bacteri
pathogen
aecopd
sputum
contain
viral
pathogen
aecopd
acut
exacerb
chronic
obstruct
pulmonari
diseas
aeri
acut
exacerb
respiratori
infect
copd
male
femal
patient
copd
age
year
elig
studi
particip
provid
meet
follow
inclus
criteria
confirm
diagnosi
copd
postbronchodil
forc
expiratori
volum
fev
predict
normal
valu
fev
forc
vital
capac
fvc
consist
gold
stage
iiiv
diseas
current
exsmok
smoke
histori
packyear
one
document
exacerb
copd
treat
antibiot
andor
steroid
month
prior
enrol
tabl
particip
recent
copd
exacerb
stabl
condit
stop
antibiot
enrol
postexacerb
exclus
criteria
includ
known
respiratori
condit
asthma
caus
respiratori
obstruct
disord
antitrypsin
defici
cystic
fibrosi
tuberculosi
lung
cancer
histori
lung
surgeri
condit
impos
pneumonia
risk
particip
longterm
corticosteroid
antibiot
therapi
time
enrol
receiv
antibiot
andor
steroid
month
prior
enrol
also
exclud
particip
seen
enrol
visit
monthli
year
regular
review
medic
requir
chang
medic
therapi
activ
smoke
cessat
advic
perform
accord
standard
clinic
practic
visit
addit
schedul
visit
particip
seen
clinic
within
h
day
onset
symptom
aecopd
aecopd
defin
worsen
least
two
major
symptom
dyspnoea
sputum
volum
sputum
purul
worsen
least
one
major
symptom
one
minor
symptom
wheez
sore
throat
cold
nasal
discharg
andor
nasal
congest
cough
fever
oral
temperatur
without
caus
consid
clinic
relev
site
exacerb
identifi
mean
electron
diari
card
particip
complet
daili
data
record
daili
electron
diari
card
includ
selfperform
peak
flow
measur
peak
expiratori
flow
pef
fev
seri
morn
question
identifi
symptom
exacerb
exacerb
chronic
pulmonari
diseas
tool
exactpro
bedtim
particip
also
ask
record
chang
usual
treatment
data
patientreport
symptom
base
morn
question
peffev
transmit
daili
studi
clinic
changesworsen
symptom
monitor
studi
staff
particip
contact
invit
clinic
exacerb
suspect
addit
daili
monitor
undertaken
patientcomplet
electron
diari
card
wide
particip
must
satisfi
follow
criteria
studi
entri
particip
investig
believ
compli
requir
protocol
written
inform
consent
obtain
particip
male
femal
age
year
confirm
diagnosi
copd
base
postbronchodil
spirometri
fev
predict
normal
fev
fvc
moder
sever
sever
copd
accord
gold
stage
histori
packyear
cigarett
smoke
document
histori
exacerb
requir
antibiot
andor
oral
corticosteroid
hospitalis
previou
month
exclus
criteria
confirm
diagnosi
asthma
caus
obstruct
respiratori
disord
cystic
fibrosi
pneumonia
risk
factor
respiratori
disord
eg
tuberculosi
lung
cancer
etc
histori
lung
surgeri
antitrypsin
defici
underli
caus
copd
moder
sever
copd
exacerb
resolv
least
month
prior
enrol
less
day
follow
last
dose
oral
corticosteroid
longterm
corticosteroid
antibiot
therapi
use
antibacteri
antivir
respiratori
investig
drug
vaccin
within
day
enrol
visit
evid
alcohol
drug
abus
presenc
condit
princip
investig
judg
may
interfer
studi
find
risk
noncompli
inabl
compli
studi
procedur
women
pregnant
lactat
plan
becom
pregnant
studi
former
smoker
defin
stop
smoke
least
month
pack
year
number
cigarett
per
year
smoke
recent
copd
exacerb
stabl
condit
stop
antibiot
enrol
month
postexacerb
enrol
aecopd
pneumonia
resolv
aecopd
acut
exacerb
chronic
obstruct
pulmonari
diseas
fev
forc
expiratori
volum
fvc
forc
vital
capac
gold
global
initi
chronic
obstruct
lung
diseas
rang
studi
procedur
perform
studi
entri
schedul
monthli
visit
exacerb
visit
tabl
quantit
highresolut
ct
scan
perform
enrol
studi
conclus
describ
degre
bronchiectasi
emphysema
note
exclud
acut
evolv
lung
patholog
besid
copd
sequela
copd
physic
examin
perform
visit
medic
histori
smoke
statu
detail
medic
use
updat
monthli
influenza
pneumococc
vaccin
statu
updat
annual
lung
function
test
perform
use
spirometri
bodi
plethysmographi
lung
volum
bodi
box
singl
breath
diffus
ga
transfer
transfer
factor
tlco
specifi
visit
follow
outcom
record
spirometri
fev
fvc
fev
fvc
ratio
fev
predict
midexpiratori
flow
fvc
singl
breath
diffus
tlco
rate
carbon
monoxid
uptak
kco
bodi
plethysmographi
total
lung
capac
tlc
residu
volum
rv
vital
capac
rvtlc
enrol
visit
particip
ask
refrain
use
shortact
bronchodil
least
h
longact
bronchodil
least
h
key
procedur
prior
subsequ
followup
visit
particip
may
use
usual
medic
normal
lung
function
measur
perform
control
condit
sit
posit
per
standard
practic
anthropometr
includ
restrict
height
weight
waist
midarm
circumfer
tricep
skinfold
circumfer
measur
quarterli
grip
strength
fatig
measur
use
standard
techniqu
anthropometr
data
use
comput
malnutrit
univers
screen
tool
must
score
nutrit
inform
includ
plannedunplan
weight
loss
histori
chang
food
intak
pattern
collect
quarterli
accord
must
guidelin
posteroanterior
chest
xray
later
requir
perform
exacerb
visit
per
standard
clinic
practic
order
rule
pneumonia
questionnair
patientreport
outcom
instrument
variou
outcom
assess
quarterli
exacerb
use
seri
questionnair
patientreport
outcom
instrument
copd
assess
test
cat
nottingham
extend
activ
daili
live
neadl
scale
council
nutrit
appetit
questionnair
cnaq
five
item
includ
index
mobil
selfcar
usual
activ
paindiscomfort
anxietydepress
bode
index
bodymass
index
degre
airflow
obstruct
level
function
dyspnoea
exercis
capac
also
calcul
healthcar
use
record
visit
includ
medic
vaccin
oxygen
therapi
use
mechan
ventil
pulmonari
rehabilit
treatment
surgic
intervent
outpati
visit
includ
gener
practition
visit
telephon
contact
copd
team
emerg
room
visit
hospitalis
product
loss
time
miss
work
usual
activ
due
worsen
copd
symptom
potenti
chang
diseas
manag
follow
exacerb
eg
chang
medic
use
also
record
wide
rang
biolog
specimen
collect
studi
particip
tabl
blood
sampl
collect
patient
studi
entri
quarterli
exacerb
sputum
sampl
obtain
spontan
expector
induc
stimul
accord
standard
method
patient
studi
entri
monthli
exacerb
nasopharyng
swab
collect
patient
studi
entri
subcohort
patient
monthli
followup
visit
exacerb
first
year
followup
urin
sampl
collect
patient
studi
entri
exacerb
subcohort
patient
monthli
followup
visit
first
year
breath
sampl
collect
approxim
patient
includ
subcohort
patient
provid
nasopharyng
swab
monthli
followup
visit
exacerb
visit
first
year
blood
sampl
analys
diseaserel
biomark
biochemistri
cellmedi
immun
respons
rna
profil
nutrient
sputum
sampl
process
tradit
cultur
techniqu
multiplex
pcr
analysi
identif
potenti
respiratori
pathogen
includ
limit
nontyp
h
influenza
catarrhali
pneumonia
p
aeruginosa
staphylococcu
aureu
respiratori
syncyti
viru
parainfluenza
viru
rhinoviru
human
metapneumoviru
influenza
viru
adenoviru
coronaviru
sputum
sampl
may
also
analys
diseaserel
biomark
nasopharyng
swab
process
tradit
cultur
techniqu
multiplex
pcr
analysi
potenti
pathogen
identif
urin
sampl
may
process
diseaserel
biomark
breath
sampl
analys
select
ion
flow
tube
mass
spectrometri
identif
volatil
organ
compound
may
characterist
aecopd
laboratori
assay
perform
public
health
laboratori
public
health
england
univers
hospit
southampton
foundat
nation
health
servic
nh
trust
glaxosmithklin
gsk
vaccin
central
laboratori
gsk
vaccin
design
laboratori
assay
use
standardis
valid
procedur
aliquot
biolog
sampl
process
applic
frozen
store
possibl
diseaserel
test
cultur
isol
also
store
addit
laboratori
test
perform
gsk
design
laboratori
sampl
size
calcul
base
primari
studi
endpoint
incid
allcaus
aecopd
assum
averag
particip
observ
period
month
two
episod
aecopd
expect
per
particip
per
year
particip
follow
number
total
personyear
would
around
time
around
exacerb
event
would
detect
distribut
event
per
particip
follow
poisson
distribut
overdispers
overdispers
factor
overdispers
approxim
valu
lower
upper
bound
ci
around
point
estim
two
event
per
particip
per
year
would
respect
sampl
size
particip
ensur
suffici
precis
estim
incid
rate
allcaus
aecopd
addit
order
follow
particip
effect
given
fact
particip
may
elig
withdraw
quit
earli
studi
possibl
due
deterior
particip
health
decis
taken
replac
particip
withdrew
first
year
followup
recruit
addit
particip
construct
consort
diagram
captur
possibl
reason
screen
failur
dropout
loss
followup
primari
studi
endpoint
occurr
allcaus
aecopd
occurr
aecopd
sputum
contain
bacteri
pathogen
detect
cultur
overal
speci
proport
particip
visit
sputum
sampl
obtain
comput
overal
method
sampl
obtain
spontan
induc
proport
sputum
sampl
obtain
visit
posit
specif
bacteri
pathogen
overal
bacteri
speci
also
calcul
incid
rate
allcaus
aecopd
aecopd
sputum
contain
bacteri
pathogen
overal
bacteri
speci
calcul
ci
ci
incid
rate
comput
use
model
account
repeat
event
name
generalis
linear
model
assum
neg
binomi
distribut
respons
variabl
logarithm
link
function
logarithm
time
followup
offset
variabl
preliminari
approach
flexibl
approach
statist
analysi
may
also
use
addit
model
covari
eg
smoke
statu
enrol
number
moder
sever
exacerb
report
month
prior
enrol
presenc
respiratori
pathogen
bacteria
detect
exacerb
visit
previou
visit
appli
incid
rate
also
calcul
moder
aecopd
sever
aecopd
particip
must
provid
written
inform
consent
particip
aeri
conduct
specialis
hospit
extens
experi
respiratori
research
aecopd
proactiv
identifi
patientcomplet
electron
diari
confirm
phone
symptom
exacerb
trigger
clinic
visit
within
h
symptom
onset
enabl
comparison
sampl
patient
stabl
copd
aecopd
although
intens
studi
prolong
followup
patient
expect
benefit
improv
access
expert
care
result
obtain
dissemin
present
intern
medic
confer
peerreview
public
report
accord
strobe
guidanc
aeri
studi
initi
comprehens
assess
role
infecti
pathogen
aecopd
wellcharacteris
cohort
patient
studi
aim
explor
dynam
airway
infect
possibl
contribut
aecopd
well
potenti
role
chronic
colonis
stabl
diseas
overal
object
studi
aim
refin
case
definit
aecopd
reflect
possibl
microbiolog
aetiolog
exacerb
note
sinc
current
commonli
agre
definit
aecopd
current
case
definit
includ
microbiolog
endpoint
impact
aecopd
healthrel
qualiti
life
healthcar
use
assess
order
provid
complet
pictur
diseas
burden
interact
airway
infect
system
manifest
copd
nutrit
statu
also
assess
detail
first
time
biolog
specimen
collect
studi
may
also
use
diseaserel
test
includ
molecular
type
describ
compar
select
biomark
aecopd
stabl
copd
explor
cellmedi
immun
respons
specif
bacteri
antigen
develop
noninvas
bacteri
diagnost
method
knowledg
studi
employ
realtim
electron
track
symptom
identifi
aecopd
potenti
aetiolog
trigger
import
sinc
avail
data
suggest
exacerb
may
report
healthcar
provid
consequ
exacerb
rate
lower
studi
employ
eventbas
criteria
defin
aecopd
due
close
daili
monitor
symptom
identifi
aecopd
anticip
exacerb
rate
studi
higher
previous
report
close
monitor
earli
therapeut
intervent
exacerb
may
also
impact
estim
overal
burden
diseas
number
epidemiolog
studi
initi
recent
year
characteris
understand
natur
histori
aecopd
howev
import
recognis
studi
includ
molecular
microbiolog
assess
recent
larg
observ
studi
focus
biomark
discoveri
involv
close
phenotyp
patient
copd
studi
aetiolog
exacerb
depth
anoth
studi
potenti
pathogen
bacteri
strain
identifi
use
molecular
type
techniqu
although
virus
potenti
airway
pathogen
investig
recent
preval
load
airway
bacteria
stabl
exacerb
aecopd
assess
pair
sampl
patient
particip
london
copd
cohort
studi
use
modern
molecular
techniqu
airway
bacteri
preval
load
found
increas
significantli
aecopd
quantit
molecular
techniqu
prove
discriminatori
cultur
howev
assess
limit
three
commonli
detect
airway
bacteria
h
influenza
pneumonia
catarrhali
howev
potenti
pathogen
overal
respiratori
microbiom
may
also
contribut
yet
studi
detail
aeri
sampl
acquir
aecopd
stabl
diseas
analys
wide
rang
potenti
pathogen
bacteria
virus
use
advanc
pcrbase
techniqu
well
tradit
culturebas
method
major
strength
aeri
studi
design
comprehens
assess
clinic
statu
microbiolog
function
statu
nutrit
statu
healthrel
qualiti
life
healthcar
resourc
utilis
individu
patient
singl
larg
cohort
stabl
copd
aecopd
select
particip
histori
least
singl
exacerb
enrich
cohort
degre
ensur
adequ
number
exacerb
sampl
accept
aspect
analysi
may
generalis
subgroup
patient
never
exacerb
analys
propos
studi
gener
epidemiolog
data
complement
deriv
exist
copd
cohort
explor
determin
copd
contribut
bacteri
viral
pathogen
aecopd
well
provid
understand
limit
exist
data
exacerb
visit
trigger
patient
diari
data
accur
time
diari
complet
essenti
particip
studi
receiv
diari
train
enrol
support
avail
studi
team
time
promot
accur
complet
diari
keep
cohort
retent
key
factor
success
deliveri
studi
indepth
sampl
protocol
particip
engag
comfort
feedback
key
factor
optimis
cohort
retent
comprehens
data
collect
identif
novel
approach
prevent
aecopd
import
research
goal
longact
laba
longact
antimuscarin
bronchodil
remain
cornerston
treatment
patient
copd
combin
laba
inhal
corticosteroid
also
use
patient
sever
diseas
andor
frequent
exacerb
longterm
treatment
macrolid
antibiot
puls
quinolon
therapi
may
consid
exacerb
prevent
howev
concern
exist
potenti
develop
antimicrobi
resist
longterm
antibiot
therapi
numer
approach
investig
prevent
aecopd
includ
antiinflammatori
drug
immunomodulatori
agent
immunotherapi
antioxid
nonpharmacolog
strategi
vaccin
anoth
potenti
approach
merit
investig
reduc
aecopd
risk
howev
optim
strategi
target
key
respiratori
pathogen
yet
avail
clinician
conclus
consider
advanc
understand
epidemiolog
pathophysiolog
clinic
manag
copd
recent
year
howev
remain
genuin
need
explor
aetiolog
pathogenesi
aecopd
anticip
result
epidemiolog
studi
increas
understand
contribut
bacteri
viral
pathogen
aecopd
natur
histori
event
associ
time
symptom
physiolog
chang
offer
new
direct
research
target
therapeut
prevent
intervent
receiv
grant
advisori
board
fee
assist
attend
confer
gsk
also
receiv
fee
lectur
advisori
board
teach
novarti
astrazeneca
boehring
ingelheim
sc
also
receiv
project
grant
support
confer
fund
attend
advisori
board
payment
pfizer
gsk
novarti
payment
made
employ
institut
tw
also
receiv
travel
expens
fee
advisori
board
gsk
relat
studi
fee
advisori
board
pfizer
astrazeneca
reimburs
travel
confer
attend
boehring
ingelheim
consult
fee
almiral
financi
support
novarti
retroscreen
travel
expens
consult
project
support
cost
cc
ea
smv
jmd
wrb
employ
gsk
cc
ea
jmd
wrb
also
report
gsk
stock
option
ethic
approv
aeri
acut
exacerb
respiratori
infect
copd
studi
conduct
accord
declar
helsinki
good
clinic
practic
guidelin
approv
relev
institut
ethic
review
board
southampton
ethic
board
proven
peer
review
commiss
extern
peer
review
open
access
open
access
articl
distribut
accord
creativ
common
attribut
non
commerci
cc
bync
licens
permit
other
distribut
remix
adapt
build
upon
work
noncommerci
licens
deriv
work
differ
term
provid
origin
work
properli
cite
use
noncommerci
see
http
